NCT02609776 2026-04-13CHRYSALISJanssen Research & Development, LLCPhase 1 Active not recruiting751 enrolled 2 FDA
NCT04077463 2026-04-13Chrysalis-2Janssen Research & Development, LLCPhase 1 Active not recruiting701 enrolled
NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled